
Product Name	: Dalazatide TFA	H-[pY)-(AEEA)-Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Met-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys-NH ₂ (disulfide bridge: Cys5-Cys37, Cys14-Cys30, Cys19-Cys34) (TFA salt)
Cat. No.	: PC-28406	
CAS No.	:	
Molecular Formula	: C ₁₈₄ H ₂₉₆ N ₅₇ O ₅₅ PS ₇ .xC ₂ HF ₃ O ₂	
Molecular Weight	: 4442.10 (free acid)	
Target	: Potassium Channel	
Solubility	: 10 mM in DMSO	

Biological Activity

Dalazatide TFA (ShK-186) is a potent, selective inhibitor of voltage-gated potassium channel Kv1.3 with IC₅₀ of 69 pM, exhibits enhanced selectivity for Kv1.3 over Kv1.1, alleviates obesity and insulin resistance.

Dalazatide (ShK-186) reduced weight gain, adiposity, and fatty liver; decreased blood levels of cholesterol, sugar, HbA1c, insulin, and leptin; and enhanced peripheral insulin sensitivity.

Dalazatide (ShK-186) activated brown adipose tissue as evidenced by a doubling of glucose uptake, and increased β-oxidation of fatty acids, glycolysis, fatty acid synthesis, and uncoupling protein 1 expression.

Dalazatide (ShK-186) caused profound alterations in energy and lipid metabolism in obesity diet induced Kv1.3 expression in the liver.

References

Victor Chi, et al. Toxicon. 2012 Mar 15;59(4):529-46.

Wen-Jun Zhen, et al. Eur J Med Chem. 2026 Sep 19:320:119310.

Upadhyay SK, et al. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):E2239-48.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com
